Unicycive Therapeutics Q4 2025: $0.82 EPS Loss, Near‑Break‑Even FinancialsUnicycive Therapeutics reports Q4 2025 results: a $0.82 per-share loss, narrowing from $2.60 last year, and near‑break‑even full‑year EPS of $1.67.Unicycive Therapeutics Inc Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 01/04/2026, 20:44 3 minutes to read
